Ulcerative Colitis | Pharmacor | G7 | 2014
Last Updated 3 November 2014
Approximately 1.2 million people in the major pharmaceutical markets under study (United States, France, Germany, Italy, Spain, United Kingdom, and Japan) are diagnosed with ulcerative colitis (UC). The conventional therapies, including aminosalicylates and corticosteroids, are often successfully used to treat mild to moderate UC, but new pharmacotherapies are needed that more effectively treat moderate to severe disease and maintain disease remission better than existing drugs (immunosuppressants and the tumor necrosis factor-alpha [TNF-α] inhibitors). The cell adhesion molecule (CAM) inhibitor vedolizumab (Takeda’s Entyvio) recently launched for moderate to severe UC, and the oral Janus-activated kinase (Jak) inhibitor tofacitinib (Pfizer’s Xeljanz) is in late-stage development. This report provides a detailed analysis and an annualized ten-year forecast of the UC therapy market extending into 2023. Included are epidemiological estimates and in-depth coverage of current treatments and emerging therapies.
